The BioPharm Brief: CAR-T Progress, ADC Momentum, Biosimilar Expansion

Jun 11, 08:41 PM
Headliner
Share
Subscribe

New developments in CAR-T cell therapy, antibody-drug conjugates, and biosimilars highlight continued innovation across oncology and immunology.

Share
Subscribe
Next
BioPharm Brief: Dermatology, Neurology, and Oncology Updates
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Regulatory Shifts, Rare Disease Innovation, and Precision Drug Development Trends
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief